Cost-effectiveness of Wisconsin TEAM model for improving adherence and hypertension control in black patients

被引:17
作者
Shireman, Theresa I. [1 ]
Svarstad, Bonnie L. [2 ]
机构
[1] Brown Univ, Sch Publ Hlth, Hlth Serv Policy & Practice, 121 South Main St,G-S121-6, Providence, RI 02912 USA
[2] Univ Wisconsin Madison, Sch Pharm, Madison, WI USA
关键词
BLOOD-PRESSURE CONTROL; RANDOMIZED CLINICAL-TRIAL; PHARMACIST COLLABORATION; INTERVENTIONS; MANAGEMENT; THERAPY; CARE; DISPARITIES; PHYSICIAN; PROGRAM;
D O I
10.1016/j.japh.2016.03.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To assess the cost-effectiveness of the 6-month Team Education and Adherence Monitoring (TEAM) intervention for black patients with hypertension in community pharmacies using prospectively collected cost data. Design: Cost-effectiveness analysis of a cluster-randomized trial. Setting: Twenty-eight chain pharmacies in 5 Wisconsin cities from December 2006 to February 2009. Participants: Five hundred seventy-six black patients with uncontrolled hypertension. Intervention: Pharmacists and pharmacy technicians using novel tools for improving adherence and feedback to patients and physicians as compared to information-only control group. Main outcome measures: Incremental cost analysis of variable costs from the pharmacy perspective captured prospectively at the participant level. Outcomes (effect measures) were 6-month refill adherence, changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and proportion of patients achieving blood pressure (BP) control. Results: Mean cost of intervention personnel time and tools was $104.8 +/- $45.2. Incremental variable costs per millimeter of mercury decrease in SBP and DBP were $22.2 +/- 16.3 and $66.0 +/- 228.4, respectively. The cost of helping 1 more person achieve the BP goal (<140/90 mm Hg) was $665.2 +/- 265.2; the cost of helping 1 more person achieve good refill adherence was $463.3 +/- 110.7. Prescription drug costs were higher for the TEAM group ($392.8 [SD = 396.3] versus $307.0 [SD = 295.2]; P = 0.02). The startup cost for pharmacy furniture, equipment, and privacy screen was $ 168 per pharmacy. Conclusion: Our randomized, practice-based intervention demonstrates that community pharmacists can implement a cost-effective intervention to improve hypertension control in blacks. This approach imposes a nominal expense at the pharmacy level that can be integrated into the ongoing pharmacist-patient relationship, and can enhance clinical and behavioral outcomes. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
[21]   Improving Medication Adherence in Patients with Hypertension: A Randomized Trial [J].
Hedegaard, Ulla ;
Kjeldsen, Lene Juel ;
Pottegard, Anton ;
Henriksen, Jan Erik ;
Lambrechtsen, Jess ;
Hangaard, Jorgen ;
Hallas, Jesper .
AMERICAN JOURNAL OF MEDICINE, 2015, 128 (12) :1351-1361
[22]   Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China [J].
Wang, Zengwu ;
Chen, Zuo ;
Wang, Xin ;
Hao, Guang ;
Ma, Liyuan ;
Zhao, Xin ;
Li, Yang ;
Zhang, Linfeng ;
Zhu, Manlu .
JOURNAL OF HYPERTENSION, 2017, 35 (04) :886-892
[23]   Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain [J].
Rodriguez-Leor, Oriol ;
Ryschon, Anne M. ;
Cao, Khoa N. ;
Jaen-Aguila, Fernando ;
Garcia-Camarero, Tamara ;
Mansilla-Morales, Carlos ;
Kolovetsios, Michael ;
Alvarez-Orozco, Maria ;
Garcia-Donaire, Jose Antonio ;
Pietzsch, Jan B. .
REC-INTERVENTIONAL CARDIOLOGY, 2024, 6 (04) :305-312
[24]   A cost-effectiveness analysis of the Chronic Disease Management Program in patients with hypertension in Korea [J].
Kim, Woorim ;
Lee, Sang Ah ;
Chun, Sung-Youn .
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2021, 33 (02)
[25]   Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients [J].
Morizio, Paige ;
Burkhart, Jena I. ;
Ozawa, Sachiko .
ANNALS OF PHARMACOTHERAPY, 2018, 52 (10) :1031-1041
[26]   DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model [J].
Wordsworth, Sarah ;
Leal, Jose ;
Blair, Edward ;
Legood, Rosa ;
Thomson, Kate ;
Seller, Anneke ;
Taylor, Jenny ;
Watkins, Hugh .
EUROPEAN HEART JOURNAL, 2010, 31 (08) :926-935
[27]   A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities [J].
Arnold, Matthias ;
Griffin, Susan ;
Ochalek, Jessica ;
Revill, Paul ;
Walker, Simon .
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
[28]   Cost-Effectiveness of Renin-Guided Treatment of Hypertension [J].
Smith, Steven M. ;
Campbell, Jonathan D. .
AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (11) :1303-1310
[29]   Cost-Effectiveness of a Multicomponent Primary Care Intervention for Hypertension [J].
Chay, Junxing ;
Jafar, Tazeen H. ;
Su, Rebecca J. ;
Shirore, Rupesh M. ;
Tan, Ngiap Chuan ;
Finkelstein, Eric A. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (08)
[30]   A systematic review of the cost and cost-effectiveness of telehealth for patients suffering from chronic obstructive pulmonary disease [J].
Udsen, Flemming W. ;
Hejlesen, Ole ;
Ehlers, Lars H. .
JOURNAL OF TELEMEDICINE AND TELECARE, 2014, 20 (04) :212-220